Sunil Gandhi

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study

Hani M. Babiker, Vincent J. Picozzi, Sreenivasa R Chandana, Hao Chunyi et autres

cn, us, es, cz, kr, jp, de, pl, hu, fr, au, be (code pays fourni par la source)

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer

Gerald S. Falchook, James A. Reeves, Sunil Gandhi, David R. Spigel et autres

gb, us (code pays fourni par la source)

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau et autres

es, hk, us, cn, jp, th, de, kr, it, fr, ca, vn, in, ru, ua, br, pl, ie (code pays fourni par la source)

A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

Pavlos Msaouel, Randy F. Sweis, Manojkumar Bupathi, Elisabeth I. Heath et autres

us (code pays fourni par la source)

RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).

Joshua E. Reuss, Sunil Gandhi, David R. Spigel, Pasi A. Jänne et autres

us, es, it (code pays fourni par la source)

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence et autres

us, it, nz, es, gb, fr (code pays fourni par la source)

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xīn Gào, Howard A. Burris, Jacqueline Vuky, Robert Dreicer et autres

us (code pays fourni par la source)

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola Jane Lawrence et autres

us, it, nz, es, gb, fr (code pays fourni par la source)

705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)

Pavlos Msaouel, Arlene O. Siefker‐Radtke, Randy F. Sweis, Shifeng Mao et autres

us (code pays fourni par la source)

Podium Session 1: Prostate Cancer June 26, 2016 1050–1150

D. Robert Siemens, Henry Klotz, Axel Heidenreich, Susmita Chowdhury et autres

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide

Eunice S. Wang, Roger M. Lyons, Sunil Gandhi, Delong Liu et autres

us (code pays fourni par la source)

Diagnosis of Metastatic Breast Cancer—A Case Report Using Molecular Cancer Classification

Yogesh S. Gandhi, Sunil Gandhi, Intern